| Literature DB >> 31933659 |
Yousuke Taniguchi1, Kenichi Sakakura1, Koichi Yuri2, Yusuke Imamura2, Takunori Tsukui1, Kei Yamamoto1, Hiroshi Wada1, Shin-Ichi Momomura1, Atsushi Yamaguchi2, Hideo Fujita1.
Abstract
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) has grown to be an alternative treatment for severe symptomatic aortic valve stenosis (AS) in elderly patients. Although TAVI is a less invasive surgery than surgical aortic valve replacement, some patients may require prolonged hospitalization. AIM: To find the determinants of prolonged hospitalization in patients who underwent trans-femoral TAVI.Entities:
Keywords: aortic valve stenosis; chopsticks; hospitalization periods
Year: 2019 PMID: 31933659 PMCID: PMC6956457 DOI: 10.5114/aic.2019.90217
Source DB: PubMed Journal: Postepy Kardiol Interwencyjnej ISSN: 1734-9338 Impact factor: 1.426
Figure 1Flowchart of patient inclusion: a flowchart of how to determine the final study population, conventional hospitalization group and prolonged hospitalization group
TAVI – trans-catheter aortic valve implantation.
Comparison of baseline characteristics
| Parameter | Overall ( | Conventional hospitalization ( | Prolonged hospitalization ( | |
|---|---|---|---|---|
| Age [years] | 83.7 ±5.1 | 83.7 ±4.7 | 83.7 ±6.6 | 0.97 |
| Female gender, | 56 (59.6) | 45 (60.8) | 11 (55.0) | 0.64 |
| Height [cm] | 152.4 ±9.4 | 152.1 ±9.6 | 153.6 ±8.8 | 0.53 |
| Weight [kg] | 51.7 ±10.8 | 51.4 ±10.2 | 53.1 ±13.0 | 0.75 |
| Body surface area (BSA) [m2] | 1.49 ±0.18 | 1.49 ±0.18 | 1.52 ±0.20 | 0.77 |
| Smoking, | 10 (10.6) | 7 (9.5) | 3 (15.0) | 0.36 |
| Chopsticks user, | 85 (90.4) | 72 (97.3) | 13 (65.0) | < 0.001 |
| ADHF, | 56 (59.6) | 40 (54.1) | 16 (80.0) | 0.04 |
| Hypertension, | 75 (79.8) | 62 (83.8) | 13 (65.0) | 0.07 |
| Dyslipidemia, | 34 (36.2) | 28 (37.8) | 6 (30.0) | 0.52 |
| Diabetes mellitus, | 21 (22.3) | 18 (24.3) | 3 (15.0) | 0.29 |
| History of atrial fibrillation, | 15 (16.0) | 9 (12.2) | 6 (30.0) | 0.06 |
| Old cerebral infarction, | 9 (9.6) | 7 (9.5) | 2 (10.0) | 0.61 |
| History of COPD/IP, | 9 (9.6) | 7 (9.5) | 2 (10.0) | 0.61 |
| Malignant diseases, | 9 (9.6) | 6 (8.1) | 3 (15.0) | 0.29 |
| Recent PCI, | 13 (13.8) | 11 (14.9) | 2 (10.0) | 0.44 |
| Laboratory data: | ||||
| Albumin [g/dl] | 3.9 ±0.4 | 4.0 ±0.4 | 3.8 ±0.5 | 0.02 |
| Creatinine [mg/dl] | 1.10 ±0.98 | 0.98 ±0.62 | 1.57 ±1.70 | 0.01 |
| eGFR [ml/min/1.73 m2] | 54.3 ±23.0 | 57.5 ±23.2 | 42.7 ±18.4 | 0.01 |
| Hemoglobin [g/dl] | 11.6 ±1.8 | 11.7 ±1.8 | 11.1 ±1.8 | 0.16 |
| Platelet [× 105/µl] | 21.0 ±18.6 | 22.0 ±20.6 | 17.4 ±7.0 | 0.27 |
| PT-INR | 1.11 ±0.41 | 1.06 ±0.21 | 1.31 ±0.78 | 0.06 |
| APTT [s] | 34.0 ±7.8 | 33.0 ±4.8 | 37.8 ±13.8 | 0.21 |
| BNP [pg/ml] | 571.7 ±1027.2 | 531.8 ±1084.8 | 731.3 ±758.5 | 0.08 |
| Electrocardiogram: | ||||
| Atria-ventricular block, | 12 (12.8) | 7 (9.5) | 5 (25.0) | 0.08 |
| RBBB, | 12 (12.8) | 9 (12.2) | 3 (15.0) | 0.49 |
| LBBB, | 6 (6.4) | 4 (5.4) | 2 (10.0) | 0.38 |
| Echocardiogram: | ||||
| LVEF (%) | 63.0 ±12.8 | 63.4 ±12.6 | 61.8 ±13.4 | 0.74 |
| Left atrial diameter [mm] | 46.9 ±7.5 | 46.4 ±7.4 | 48.7 ±7.7 | 0.24 |
| LVD diastole [mm] | 47.1 ±6.5 | 47.0 ±6.4 | 47.5 ±7.1 | 0.75 |
| LVD systole [mm] | 30.8 ±7.0 | 30.7 ±6.9 | 31.1 ±7.3 | 0.84 |
| E/A | 0.81 ±0.50 | 0.73 ±0.30 | 1.20 ±0.93 | 0.003 |
| Aortic valve peak velocity [m/s] | 4.74 ±0.69 | 4.77 ±0.71 | 4.64 ±0.64 | 0.57 |
| Aortic valve mean PG [mm Hg] | 56.1 ±18.9 | 56.6 ±19.6 | 54.6 ±16.7 | 0.73 |
| Aortic valve area [cm2] | 0.69 ±0.48 | 0.70 ±0.52 | 0.62 ±0.20 | 0.34 |
| Moderate or severe AR, | 21 (22.3) | 20 (27.0) | 1 (5.0) | 0.03 |
| Moderate or severe MR, | 18 (19.1) | 10 (13.5) | 8 (40.0) | 0.01 |
| Pulmonary hypertension, | 35 (37.2) | 23 (31.1) | 12 (60.0) | 0.02 |
| Medications, | ||||
| Aspirin | 36 (38.3) | 32 (43.2) | 4 (20.0) | 0.06 |
| P2Y12 inhibitors | 20 (21.3) | 18 (24.3) | 2 (10.0) | 0.14 |
| Oral anti-coagulants | 8 (8.5) | 5 (6.8) | 3 (15.0) | 0.23 |
| Statins | 35 (37.2) | 32 (43.2) | 3 (15.0) | 0.02 |
| ACE inhibitors or ARB | 47 (50.0) | 42 (56.8) | 5 (25.0) | 0.01 |
| β-blockers | 26 (27.7) | 17 (23.0) | 9 (45.0) | 0.05 |
| Diuretics | 50 (53.2) | 37 (50.0) | 13 (65.0) | 0.23 |
| Oral hypoglycemic agents | 10 (10.6) | 9 (12.2) | 1 (5.0) | 0.32 |
| Insulin user | 2 (2.1) | 2 (2.7) | 0 (0) | 0.62 |
| Inotropic agents | 2 (2.1) | 1 (1.4) | 1 (5.0) | 0.38 |
| Steroids | 6 (6.4) | 4 (5.4) | 2 (10.0) | 0.38 |
| STS score | 6.96 ±7.54 | 6.19 ±5.72 | 9.82 ±11.91 | 0.006 |
| Logistic EuroSCORE | 9.73 ±7.01 | 9.47 ±6.52 | 10.68 ±8.75 | 0.77 |
ADHF – acute decompensated heart failure, COPD – chronic obstructive pulmonary disease, IP – interstitial pneumonia, PCI – percutaneous coronary intervention, eGFR – estimated glomerular filtration rate, PT-INR – prothrombin time-international normalized ratio, APTT – activated partial thromboplastin time, BNP – brain natriuretic peptide, RBBB – right bundle branch block, LBBB – left bundle branch block, LVEF – left ventricular ejection fraction, LVD – left ventricular diameter, PG – pressure gradient, AR – aortic valve regurgitation, MR – mitral valve regurgitation, ACEI – angiotensin converting enzyme inhibitors, ARB – angiotensin II receptor blockers, STS – Society of Thoracic Surgeons.
Comparison of procedure and after TAVI
| Parameter | Overall ( | Conventional hospitalization ( | Prolonged hospitalization( | |
|---|---|---|---|---|
| Devices: | 0.39 | |||
| SapienXT | 29 (30.9) | 23 (31.1) | 6 (30.0) | |
| Sapien3 | 38 (40.4) | 32 (43.2) | 6 (30.0) | |
| Corevalve | 13 (13.8) | 8 (10.8) | 5 (25.0) | |
| EvoluteR | 14 (14.9) | 11 (14.9) | 3 (15.0) | |
| Size: | 0.21 | |||
| 20 mm | 3 (3.2) | 2 (2.7) | 1 (5.0) | |
| 23 mm | 41 (43.6) | 36 (48.6) | 5 (25.0) | |
| 26 mm | 37 (39.4) | 27 (36.5) | 10 (50.0) | |
| 29 mm | 13 (13.8) | 9 (12.2) | 4 (20.0) | |
| Operation time [min] | 148 ±49 | 151 ±54 | 136 ±22 | 0.55 |
| Exposure time [min] | 45 ±16 | 47 ±16 | 38 ±14 | 0.03 |
| Contrast volume [ml] | 163 ±69 | 167 ±72 | 147 ±55 | 0.26 |
| Complications, | ||||
| Convert to open heart surgery | 1 (1.0) | 1 (1.3) | 0 (0) | 0.78 |
| Cerebral infarction | 2 (2.1) | 0 (0) | 2 (10.0) | 0.04 |
| New pacemaker implantation | 8 (8.5) | 2 (2.7) | 6 (30.0) | 0.001 |
Figure 2Main causes of prolonged hospitalization periods
ADHF – acute decompensated heart failure, CKD – chronic kidney disease.
Multivariate logistic regression analysis
| Independent variables: “Prolonged hospitalization” | OR | 95% CI | |
|---|---|---|---|
| Current chopsticks user at admission | 0.05 | 0.01–0.41 | < 0.01 |
| Moderate or severe MR | 4.49 | 1.16–17.47 | 0.03 |
| Pre eGFR (per 15 ml/min/1.73 m2 incremental) | 0.49 | 0.26–0.90 | 0.02 |
| Statins | 0.13 | 0.02–0.71 | 0.02 |
| ACE inhibitors or ARB | 0.25 | 0.06–0.96 | 0.04 |
MR – mitral valve regurgitation, eGFR – estimated glomerular filtration rate, ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blockers. Initial step included current chopsticks user at admission, moderate or severe MR, Pre eGFR, statin, ACE inhibitors/ARB, ADHF, albumin value, right bundle branch block, atrioventricular block and STS score before procedure.